Carl Dambkowski, M.D.
Business Development and Operations
Carl Dambkowski, M.D. is VP, Business Development and Operations at QED Therapeutics. Carl joined QED with the goal of ensuring that infigratinib provides the greatest benefit to the most patients worldwide. As VP of Business Development and Operations, he is responsible for guiding QED’s corporate strategy and ensuring QED operates smoothly. Prior to QED, Carl was a consultant in McKinsey & Company’s Silicon Valley Office where he advised pharmaceutical clients specifically in the areas of R&D strategy and commercial drug launches. He did his internship in emergency medicine at Stanford University and was a co-founder of Novonate, a neonatal focused medical device company. Carl received a B.A. and an M.D. from Stanford University, as well as an M.A. from Columbia University. He holds a license to practice medicine in the state of California.